RESUMO
BACKGROUND: Prognosis for patients with gallbladder carcinoma (GBC) is poor and the standard treatment for GBC has not yet been established. MATERIALS AND METHODS: We established the human GBC cell line TYGBK-1, from a patient with papillary, tubular adenocarcinoma. RESULTS: The doubling time was 48 hours. This cell line has a missense mutation of p53 and no mutation of the K-RAS gene. This cell line was transplantable to nude mice. We characterized the sensitivity of TYGBK-1 to gemcitabine. We also examined the association of two gemcitabine-related genes (deoxycytidine kinase, dCK, and Hu antigen R, HuR). Among four GBC cell lines (TYGBK-1, NOZ, G-415, TGBC2TKB), TYGBK-1 and NOZ exhibited sensitivity to gemcitabine. Furthermore, these cells expressed both dCK and HuR mRNA, rather than gemcitabine-resistant cells. CONCLUSION: The newly established GBC cell line TYGBK-1, may represent an effective tool for development of chemotherapeutic treatment for GBC.
Assuntos
Adenocarcinoma/patologia , Neoplasias da Vesícula Biliar/patologia , Adenocarcinoma/genética , Adenocarcinoma Papilar/genética , Adenocarcinoma Papilar/patologia , Idoso , Animais , Sequência de Bases , Linhagem Celular Tumoral , Primers do DNA , Feminino , Neoplasias da Vesícula Biliar/genética , Genes p53 , Genes ras , Humanos , Imuno-Histoquímica , Camundongos , Camundongos Nus , Mutação de Sentido Incorreto , Reação em Cadeia da Polimerase em Tempo RealRESUMO
A 58-year-old man underwent a high anterior resection for rectal cancer in May, 2005.T he pathological finding was stage IIIa, and he therefore started taking UFT in August, 2005.H e had dyspnea in August, 2006, however, and his diagnosis was lymphangitis carcinomatosa of the lung.mFOLFOX6 was started in the same month.Although the dose was reduced because of side effects, chemotherapy was performed for 26 courses.In November, 2007, however, computed tomography(CT) showed that the lymphangitis carcinomatosa had worsened and that a mass lesion had appeared at the S8 segment of the liver.Therefore, FOLFIRI was started in December, 2007. After that, the lesions were stable disease.Bevacizumab was added in August, 2008, but the lung lesion had worsened by May, 2009, and the chemotherapy was therefore changed to CPT-11 and cetuximab.The lesion and his condition were gradually getting worse, however, and he was admitted to the hospital for dyspnea in January, 2010.H e died the following month.Although lymphangitis carcimonatosa causing colorectal cancer is very rare and known to have a poor prognosis, we experienced a case of about 41-months long survival.This case is reported together with some bibliographical comments here.